Malarone

Pneumonia, Pneumocystis, Genus Pneumocystis, prophylaxis of Pneumocystis jiroveci pneumonia + 8 more
Treatment
4 FDA approvals
20 Active Studies for Malarone

What is Malarone

AtovaquoneThe Generic name of this drug
Treatment SummaryAtovaquone is an anti-malarial medication that works by targeting a specific type of bacteria and preventing the growth of the malaria-causing parasite. It is a type of hydroxynaphthoquinone, a chemical that is similar to ubiquinone, and is used in antimalarial treatments.
Mepronis the brand name
image of different drug pills on a surface
Malarone Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Mepron
Atovaquone
1995
52

Approved as Treatment by the FDA

Atovaquone, otherwise called Mepron, is approved by the FDA for 4 uses which include acute, uncomplicated Malaria caused by plasmodium falciparum and Malaria caused by Plasmodium falciparum .
acute, uncomplicated Malaria caused by plasmodium falciparum
Used to treat acute, uncomplicated Malaria caused by plasmodium falciparum in combination with Proguanil
Malaria caused by Plasmodium falciparum
Used to treat Malaria caused by Plasmodium falciparum in combination with Proguanil
Malaria
Used to treat acute, uncomplicated Malaria caused by plasmodium falciparum in combination with Proguanil
Malaria
Used to treat Malaria caused by Plasmodium falciparum in combination with Proguanil

Effectiveness

How Malarone Affects PatientsAtovaquone is a fat-soluble drug that is similar in structure to ubiquinone. It works by targeting certain processes in parasites, such as energy production and the creation of a certain type of molecule. Atovaquone has been found to target a specific part of the energy making process in the parasite Plasmodia. Unlike many drugs, atovaquone does not cause bone marrow suppression, making it a good choice for those who have had a bone marrow transplant.
How Malarone works in the bodyWe don't know exactly how atovaquone works to fight Pneumocystis carinii, but it appears to target enzymes involved in energy production in cells. This inhibition stops the cells from being able to make nucleic acid and ATP, which causes them to die. Atovaquone is also effective against Toxoplasma gondii when tested in a lab.

When to interrupt dosage

The recommended dosage of Malarone is contingent upon the diagnosed condition, such as prophylaxis of Pneumocystis jiroveci pneumonia, Genus Pneumocystis and Toxoplasmosis. The amount of dosage can be found in the table below, contingent upon the method of administration, including Tablet - Oral or Tablet, film coated - Oral.
Condition
Dosage
Administration
Malaria
62.5 mg, 250.0 mg, , 750.0 mg/mL, 150.0 mg/mL
, Tablet, film coated - Oral, Oral, Tablet, film coated, Tablet, Tablet - Oral, Suspension - Oral, Suspension
Malaria
62.5 mg, 250.0 mg, , 750.0 mg/mL, 150.0 mg/mL
, Tablet, film coated - Oral, Oral, Tablet, film coated, Tablet, Tablet - Oral, Suspension - Oral, Suspension
Genus Pneumocystis
62.5 mg, 250.0 mg, , 750.0 mg/mL, 150.0 mg/mL
, Tablet, film coated - Oral, Oral, Tablet, film coated, Tablet, Tablet - Oral, Suspension - Oral, Suspension
Babesiosis
62.5 mg, 250.0 mg, , 750.0 mg/mL, 150.0 mg/mL
, Tablet, film coated - Oral, Oral, Tablet, film coated, Tablet, Tablet - Oral, Suspension - Oral, Suspension
Pneumonia, Pneumocystis
62.5 mg, 250.0 mg, , 750.0 mg/mL, 150.0 mg/mL
, Tablet, film coated - Oral, Oral, Tablet, film coated, Tablet, Tablet - Oral, Suspension - Oral, Suspension
Toxoplasmosis
62.5 mg, 250.0 mg, , 750.0 mg/mL, 150.0 mg/mL
, Tablet, film coated - Oral, Oral, Tablet, film coated, Tablet, Tablet - Oral, Suspension - Oral, Suspension
Toxoplasmosis
62.5 mg, 250.0 mg, , 750.0 mg/mL, 150.0 mg/mL
, Tablet, film coated - Oral, Oral, Tablet, film coated, Tablet, Tablet - Oral, Suspension - Oral, Suspension
Pneumonia, Pneumocystis
62.5 mg, 250.0 mg, , 750.0 mg/mL, 150.0 mg/mL
, Tablet, film coated - Oral, Oral, Tablet, film coated, Tablet, Tablet - Oral, Suspension - Oral, Suspension
prophylaxis of Pneumocystis jiroveci pneumonia
62.5 mg, 250.0 mg, , 750.0 mg/mL, 150.0 mg/mL
, Tablet, film coated - Oral, Oral, Tablet, film coated, Tablet, Tablet - Oral, Suspension - Oral, Suspension
Babesiosis
62.5 mg, 250.0 mg, , 750.0 mg/mL, 150.0 mg/mL
, Tablet, film coated - Oral, Oral, Tablet, film coated, Tablet, Tablet - Oral, Suspension - Oral, Suspension
HIV
62.5 mg, 250.0 mg, , 750.0 mg/mL, 150.0 mg/mL
, Tablet, film coated - Oral, Oral, Tablet, film coated, Tablet, Tablet - Oral, Suspension - Oral, Suspension

Warnings

There are 20 known major drug interactions with Malarone.
Common Malarone Drug Interactions
Drug Name
Risk Level
Description
Acenocoumarol
Major
The metabolism of Acenocoumarol can be decreased when combined with Atovaquone.
Acepromazine
Major
The risk or severity of QTc prolongation can be increased when Atovaquone is combined with Acepromazine.
Aceprometazine
Major
The risk or severity of QTc prolongation can be increased when Atovaquone is combined with Aceprometazine.
Acetophenazine
Major
The risk or severity of QTc prolongation can be increased when Atovaquone is combined with Acetophenazine.
Alimemazine
Major
The risk or severity of QTc prolongation can be increased when Atovaquone is combined with Alimemazine.
Malarone Toxicity & Overdose RiskThe most toxic dose of atovaquone is higher than the highest dose tested in mice and rats (1825 mg/kg/day). In some cases, people have overdosed on up to 31,500 mg of atovaquone. One patient who overdosed also reported methemoglobinemia, a condition where too much of the oxygen-carrying pigment in the blood is converted to a different form. Skin rash is also a common symptom of atovaquone overdose.
image of a doctor in a lab doing drug, clinical research

Malarone Novel Uses: Which Conditions Have a Clinical Trial Featuring Malarone?

Currently, 124 active clinical trials are evaluating the potential of Malarone in providing relief to those suffering from Malaria, Babesiosis and HIV.
Condition
Clinical Trials
Trial Phases
HIV
155 Actively Recruiting
Phase 2, Phase 1, Phase 3, Not Applicable, Phase 4, Early Phase 1
Malaria
0 Actively Recruiting
Genus Pneumocystis
0 Actively Recruiting
Toxoplasmosis
0 Actively Recruiting
Pneumonia, Pneumocystis
0 Actively Recruiting
Pneumonia, Pneumocystis
1 Actively Recruiting
Phase 3
Malaria
0 Actively Recruiting
Babesiosis
0 Actively Recruiting
Babesiosis
0 Actively Recruiting
Toxoplasmosis
0 Actively Recruiting
prophylaxis of Pneumocystis jiroveci pneumonia
0 Actively Recruiting

Malarone Reviews: What are patients saying about Malarone?

5Patient Review
5/18/2020
Malarone for Prevention of Falciparum Malaria
I took this drug for many trips to Papua New Guinea and Solomon Islands. The trips varied from one week up to four weeks. I never experienced any side effects and took this drug for a total of around 6 months over a 3 year period. [I tried an alternative anti-malarial when I ran out of Malarone on one trip - hydroxycloroquine - and had continuous stomach upsets and diarrhoea.]
3.7Patient Review
10/23/2013
Malarone for Prevention of Falciparum Malaria
I experienced weight gain and disorientation after taking this medication, as well as some pretty intense nightmares.
3.3Patient Review
8/9/2015
Malarone for Prevention of Falciparum Malaria
After just two days of taking this medication, my stool turned green. I'm not sure what that indicates, but it wasn't pleasant.
2.3Patient Review
7/24/2013
Malarone for Prevention of Falciparum Malaria
I took the drug for 16 days before I went to Africa. I don't think it had any effect; I got mosquito bites regardless. Additionally, both of my legs now have weird rashes on them that don't itch, so I'm stopping the medication early.
2.3Patient Review
2/6/2015
Malarone for Prevention of Falciparum Malaria
My experience with this medication was fine, but my boyfriend had a very different reaction. He started feeling faint and lightheaded, and his vision kept going in and out. This went on for about an hour before he finally fell asleep. Needless to say, he won't be taking this again.
2.3Patient Review
6/18/2015
Malarone for Prevention of Falciparum Malaria
About two weeks into using this medication, I started experiencing brain fog. This continued even after I stopped taking the drug.
2.3Patient Review
6/23/2012
Malarone for Prevention of Falciparum Malaria
My family and I recently traveled to the Rift Valley region of Kenya. Two of us took Malarone, two took nothing....all four of us were clinically diagnosed with malaria 2-4 times...person 1 on malarone...3 times in Kenya and a relapse in America. person 2 on malarone 2 rounds in Kenya. Person 3 no prophylaxis 3 rounds in Kenya one on return. Person 4 no malarone 2 rounds in Kenya 0 at home. Med seems to have no effect on malaria in the area we were staying...and no reduction in severity of symptoms
1Patient Review
8/5/2017
Malarone for Prevention of Falciparum Malaria
Malarone gave me terrible diarrhea four days into my trip to Tanzania. The doctor at the lodge said it was because of the Malarone and had me stop taking it. I had to take a lot of imodium for the rest of my trip and even when I got back home.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about malarone

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Malarone an antibiotic?

"Malarone is an antibiotic that is indicated to treat a wide range of bacterial infections. In severe acne, Malarone may be useful as adjunctive therapy."

Answered by AI

What does Malarone do to your body?

"Malarone helps to prevent the growth of parasites in human red blood cells. These parasites usually enter the body through a mosquito bite and can cause malaria. Malaria is common in areas of Africa, South America, and Southern Asia. Malarone can be used to help treat or prevent malaria."

Answered by AI

Who should not take Malarone?

"You should take atovaquone- proguanil with food.

If you are pregnant, have an infant that weighs less than 5kg, are nursing, have severe kidney disease, or are taking medications that affect your liver or kidney function, you should not take atovaquone-proguanil. You should take atovaquone-proguanil with food."

Answered by AI

How long is it safe to take Malarone for?

"The course should be started 1 or 2 days before entering a country with a risk of malaria and taken daily for the entire duration of your stay. The course should then be continued for 7 days after leaving the affected area."

Answered by AI

Clinical Trials for Malarone

Image of University of Alabama at Birmingham in Birmingham, United States.

Olfactory Training for HIV

18+
All Sexes
Birmingham, AL
The goal of this study is to examine two types of olfactory interventions (olfactory training vs overnight odor diffuser) in adults with HIV. The two research questions are: 1. Determine if participants find the intervention acceptable and assess feasibility of the study. 2. Determine if the intervention improves olfactory function and cognitive function. Participants will come to our office and be administered the baseline battery of questions including olfactory and cognitive performance tests. Then they will be randomized and sent home with one of the two interventions (below) in which they will engage in it for 8 weeks, after which they come back to our office for the posttest battery of questions including olfactory and cognitive performance test. 1. Olfactory Training at Home -- 4 scents in which they will smell twice a day for 8 weeks. 2. Overnight Diffuser Group -- a single scent diffuser that participants will turn on while they sleep and use for 8 weeks.
Phase < 1
Waitlist Available
University of Alabama at Birmingham
Image of Los Angeles General Medical Center in Los Angeles, United States.

Decision Support Tool for HIV Treatment

18+
All Sexes
Los Angeles, CA
This study is testing software designed to help healthcare providers choose the best HIV treatment combinations for their patients. HIV medicines, known as antiretroviral therapy (ART), can be complex to manage because the right regimen depends on many factors-such as drug resistance, other health conditions, and medication schedules. Many people with HIV are cared for by general clinicians who may not have access to HIV specialists, which can make treatment decisions more challenging. In this study, healthcare providers will use patient cases to compare standard HIV treatment resources with a new clinical decision support tool that gives evidence-based ART recommendations at the point of care. The investigators hypothesize that using the tool will help providers select treatment plans that better match clinical guidelines, make decisions faster, reduce mental effort, and increase overall satisfaction with the prescribing process.
Waitlist Available
Has No Placebo
Los Angeles General Medical CenterHayoun Lee, PhD
Image of University of North Carolina in Chapel Hill, United States.

MGD020 + MGD014 for HIV

18 - 65
All Sexes
Chapel Hill, NC
This research study aims to find out how safe and well tolerated the experimental study drugs are when given to persons with HIV (PWH) taking antiretroviral therapy (ART). The study treatments are MGD014 and MGD020, which are two antibodies developed specifically for HIV, and Vorinostat, an oral medication to help expose HIV in cells to the antibodies. The study will measure the impact of study treatment on non-active HIV in cells, and how long MGD014 and MGD020 stay in the body after they are given. In this study, participants will be randomly assigned to one of three groups. All participants receive MGD014 and MGD020, given sequentially as infusions through an IV for 4 doses. Participants in one group (group A) receive only MGD014 and MGD020. Participants in another group (group B) will stop taking their ART therapy for up to 8 weeks (a temporary treatment interruption (TTI)) while receiving MGD014 and MGD020. Participants in the third group (group C) receive Vorinostat in addition to MGD014 and MGD020. Total time of participation is about 8 months and involves 13 or 18 visits, depending on group assignment.
Phase 1
Recruiting
University of North CarolinaCynthia L. Gay, MD
Have you considered Malarone clinical trials? We made a collection of clinical trials featuring Malarone, we think they might fit your search criteria.Go to Trials
Have you considered Malarone clinical trials? We made a collection of clinical trials featuring Malarone, we think they might fit your search criteria.Go to Trials
Image of UCSF in San Francisco, United States.

N-803 for HIV

18 - 70
All Sexes
San Francisco, CA
Even though HIV medicine stops the virus from making more copies of itself, the virus remains in the body by hiding inside of immune cells. This hidden virus is referred to as the "latent reservoir." Researchers on this team are studying whether stimulating the immune system can change the nature of the latent reservoir and if this could help people control HIV without the need to take regular HIV medicine. This study is testing a drug called N-803. N-803 is also known as Interleukin-15 or "IL-15", a powerful and long lasting protein that can affect the immune system by stimulating immune cells such as CD8+ T cells and natural killer (NK) cells. CD8+ T cells and NK cells are both crucial for eliminating infected cells. The drug is FDA-approved for the treatment of bladder cancer, but in this study the drug is being used experimentally for HIV.
Phase 2
Waitlist Available
UCSF
Image of Alabama CRS (Site ID: 31788) in Birmingham, United States.

Dasatinib + Quercetin for HIV

18+
All Sexes
Birmingham, AL
This clinical trial is a Phase II study designed to test the safety and effectiveness of a combination of dasatinib and quercetin (D+Q) in improving physical function for people with HIV who are frail or prefrail. The study will involve 80 participants, all aged 50 or older, who have been living with HIV for at least 10 years determined to meet criteria for diagnosis of frail or prefrail and are currently on a stable antiretroviral therapy with viral suppression. Participants will be randomly assigned to one of two groups: one group will receive the D+Q treatment, and the other will receive a placebo. The treatment will be given in six cycles over 12 weeks, with participants taking the medication for two days followed by 12 days without treatment. After the 12-week treatment period, participants will be monitored for another 12 weeks to assess the long-term effects. The study aims to determine if D+Q can improve physical function and other health outcomes in this population. Randomization will be stratified by sex and age to ensure balanced groups.
Phase 2
Waitlist Available
Alabama CRS (Site ID: 31788) (+26 Sites)
Image of Yale University in New Haven, United States.

DynamiCare + Patient Navigation for Stimulant Use Disorder

18+
All Sexes
New Haven, CT
Justice-involved individuals face disproportionately high rates of stimulant use disorder and HIV, along with disrupted access to HIV treatment and prevention services like ART and PrEP. Contingency management (CM) is the most effective intervention for stimulant use, but its use in justice-involved populations has been limited by logistical and structural barriers. DynamiCare is an FDA-approved mobile app that delivers behavioral CM and has shown promise in reducing stimulant use, but its impact on HIV-related outcomes remains unknown. The RESTORE study (Recovery and Engagement for Stimulant Users on Re-entry) will evaluate whether combining DynamiCare with patient navigation (DynamiCare-plus) improves PrEP/ART initiation and reduces stimulant use among individuals recently released from justice settings. The R61 phase will assess feasibility, acceptability, and preliminary effectiveness among 40 participants. If milestones are met, the R33 phase will scale to a randomized controlled trial with 252 participants to assess effectiveness, implementation, and cost. This scalable, mobile approach has the potential to address a critical gap in care for a highly vulnerable population.
Waitlist Available
Has No Placebo
Yale University (+1 Sites)Ank Nijhawan, MD
Have you considered Malarone clinical trials? We made a collection of clinical trials featuring Malarone, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security